Strides Pharma Q1 FY27 Results: Net Profit Jumps 57% to ₹165.49 Crore, Revenue Crosses ₹1,265 Crore
Strides Pharma Science Limited reported a strong financial performance for the first quarter of FY2027, driven by healthy growth in revenue, higher profitability, and a significant exceptional gain from a strategic business restructuring. The company’s Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026, at its meeting held on July 31, 2026.
The results received a limited review with an unmodified opinion from the company’s statutory auditors, B S R & Co. LLP, reflecting the integrity of the financial statements.
Strides Pharma Q1 FY27 Consolidated Financial Highlights
The pharmaceutical company delivered healthy year-on-year growth across key financial metrics during the quarter.
| Particulars | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Revenue from Operations | ₹1,265.41 crore | ₹1,119.74 crore | 13.0% |
| Net Profit (PAT) | ₹165.49 crore | ₹105.59 crore | 56.7% |
| Total Comprehensive Income | ₹194.41 crore | — | — |
| Earnings Per Share (EPS) | ₹17.02 | — | — |
The strong performance reflects growth in the company’s core pharmaceutical business, supported by improved operating performance and exceptional gains recorded during the quarter.
Standalone Performance
On a standalone basis, Strides Pharma also reported solid financial performance during Q1 FY27.
- Total Income: ₹584.12 crore
- Profit Before Tax (PBT): ₹84.76 crore
- Profit After Tax (PAT): ₹72.93 crore
- Total Comprehensive Income: ₹96.18 crore
These results highlight the continued strength of the parent company’s core operations.
Exceptional Gain Boosts Earnings
A major contributor to the company’s higher quarterly profit was a net exceptional gain of ₹63.20 crore on a consolidated basis.
The gain was primarily driven by the restructuring of Pivot Path Private Limited. Following the demerger and induction of new investors, Strides diluted its stake in Pivot Path to 19.95%, resulting in the loss of control and recognition of a fair-value gain.
The company recognized:
- ₹74.21 crore exceptional gain on a consolidated basis.
- ₹76.40 crore exceptional gain on a standalone basis.
These gains were partially offset by ₹11.01 crore of expenses related to product recalls, legal settlements, and associated costs involving Ranitidine, Losartan, and Testosterone products.
Focused Pharmaceutical Business
Strides Pharma continues to operate as a single reportable pharmaceutical segment, focusing on the development, manufacturing, and commercialization of high-quality pharmaceutical products for regulated and emerging markets worldwide.
The company remains focused on expanding its portfolio of complex generic medicines while strengthening its presence across key international markets.
Final Dividend Proposed
The Board has proposed a final dividend of ₹5 per equity share, subject to shareholders’ approval at the upcoming Annual General Meeting.
The proposed dividend is expected to result in a cash outflow of approximately ₹46.10 crore, reflecting the company’s confidence in its financial position and commitment to rewarding shareholders.
Outlook
Strides Pharma continues to strengthen its global pharmaceutical business through operational improvements, strategic portfolio optimization, and expansion across regulated markets.
The successful restructuring of Pivot Path, combined with steady revenue growth and improving profitability, positions the company well for future growth. Management also remains focused on resolving legacy product recall matters while investing in new products and international market expansion.